Beam gets FDA clearance for first base editing IND (BEAM-101); Q3 net loss $28.1M, cash $933.4M

Beam Therapeutics Inc.

FDA cleared IND for BEAM-101 (sickle cell disease); first open IND for base editing.
Beam initiated IND-enabling studies for BEAM-102 (Makassar base editing for sickle cell).
Q3 net loss $28.1M ($0.42/share); R&D $54.6M, G&A $15.8M.
Cash, equivalents & securities $933.4M as of Sep 30, 2021, up from $299.7M at Dec 31, 2020.
Non-exclusive license to Sana for Cas12b for $50M upfront; potential milestones/royalties.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John Maraganore

Director

BEAM · Beam Therapeutics Inc.

Effective: 2021-11-05
Filed: November 8, 2021, 6:59 PM ET

On November 5, 2021, the Board of Directors (the “Board”) of the Company, upon recommendation from the Nominating and Corporate Governance Committee of the Board, expanded the size of the Board from six to seven members and elected John Maraganore, Ph.D., as a member of the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John Maraganore was elected as Director at Beam Therapeutics Inc..

Action: elected
Role: Director

Exact text from the filing

On November 5, 2021, the Board of Directors (the “Board”) of the Company, upon recommendation from the Nominating and Corporate Governance Committee of the Board, expanded the size of the Board from six to seven members and elected John Maraganore, Ph.D., as a member of the Board.

View on SEC.gov

Beam Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950170-21-003291

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.